Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients

Annals of Oncology

Volumn 10, Issue 9, 1999, Pages 1087-1094

  Cerny, Thomas ^a,d   Leyvraz, S ^b   Von Briel, T ^a   Kupfer A ^a   Schaad, R ^a   Hsu Schmitz, S F ^a   Honegger, P ^a   Sessa, C ^c   Brunner, J ^a   Boddy, A V ^a  

^a Kantonsspital ^*

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

High dose ifosfamide; Metabolism; Pharmacology; Sarcomas

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; ISOPHOSPHORAMIDE MUSTARD; MESNA;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; MALE; MESNA; MIDDLE AGED; PRODRUGS; PROTECTIVE AGENTS; REMISSION INDUCTION; SARCOMA; TIME FACTORS;

EID: 0032870341     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008386000547     Document Type: Article

References (38)

1. Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988; 80: 556-66.
2. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft-tissue and bone. The M.D. Anderson experience. Cancer Chemother Pharmacol 1993; 31 (Suppl 2); 174-79.
3. Connelly EF, Budd GT. Ifosfamide in the treatment of soft tissue sarcomas. Seminars in Oncology 1996; 23 (Suppl 6): 16-21.
4. Buesa JM, López-Pousa A, Martin J et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcoma of the adults: A study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998; 9: 871-6.
5. Antman K, Crowley J, Balcerzak StP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-85.
6. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European organization for research and treatment of cancer. soft tissue and bone sarcoma group. J Clin Oncol 1995; 13: 1537-45.
7. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998; 16: 1438-43.
8. Brade WP, Herdrich K, Kachel-Fischer U, Araujo CE. Dosing and side-effects of ifosfamide plus mesna. J Cancer Res Clin Oncol 1991; 117 (Suppl 4): 164-86.
9. Elias A, Eder J, Shea T et al. High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 1990; 8: 170-8.
10. Cerny T, Leyvraz S, Dazzi H et al. Phase II trials of ifosfamide and mesna in advanced soft tissue sarcoma (sts) patients: A definite dose-response relationship. Proc Am Soc Clin Oncol 1992; 11 (Abstr 1462): 416.
11. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-8.
12. Demetri GD. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Semin Oncol 1996; 23 (Suppl 6): 22-6.
13. Palumbo R, Palmeri S, Antimi M et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 1997; 8: 1159-62.
14. Patel S, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilots studies - dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-84.
15. Klein HO, Wickramanayake PD, Christian E, Coerper C. Therapeutic effects of single-push or fractionated injections or continuous infusions of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z7557). Cancer 1984; 54: 1193-203.
16. Cerny T, Castiglione M, Brunner K et al. Ifosfamide by continuous infusion to prevent encephalopathy [Letter]. Lancet 1990; 335: 175.
17. Anderson H, Hopwood P, Prendiville J et al. A randomized study of bolus versus continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. Br J Cancer 1993; 67: 1385-90.
18. Bellmunt J, Eres N, Ribas A et al. Feasibility trial of high-dose seven-day continuous ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol 1997; 40: 273-6.
19. Singer JM, Hartley JM, Brennan C et al. The pharmacokinetics and metabolisme of ifosfamide during bolus and infusional administration: A randomized cross-over study. Br J Cancer 1998; 77: 978-84.
20. Shaw IC, Graham Mi. Mesna - a short review. Cancer Treat Rev 1987; 14: 6786.
21. Goren MP, Wright RK, Pratt CB, Pell FE. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986; 2: 1219-20.
22. Lokiec F, Santoni J, Weill S et al. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Anticancer Drugs 1996; 7: 893-6.
23. Kaijser GP, Keizer HJ, Beijnen JH et al. Pharmacokinetics of ifosfamide 2-and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Anticancer Res 1996; 16: 3247-57.
24. Busse D, Busch FW, Bohnenstengel F et al. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism. J Clin Oncol 1997; 15: 1885-96.
25. Chen TL, Passos-Coelho JL, Noe DA et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 55: 810-6.
26. Lauterburg BH, Nguyen T, Hartmann B et al. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/ mesna therapy. Cancer Chemother Pharmacol 1994; 35: 132-6.
27. Castellanos AM, Fields WS. Grading of neurotoxicity in cancer therapy [Letter]. J Clin Oncol 1986; 4: 1277-8.
28. Pantarotto C, Bossi A, Berlvedere G et al. A quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens. J Pharm Sci 1974; 63: 1554-8.
29. Boddy AV, Cole M, Pearson AD, Idle JR. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995; 36: 53-60.
30. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990; 30: 725-32.
31. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993; 33: 36-42.
32. Boddy AV, Yule SM, Wyllie R et al. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 1993; 53: 3758-64.
33. Boddy AV, Proctor M, Simmonds D et al. Pharmacokinetics. metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 1995; 31A: 69-76.
34. Lewis LD. Ifosfamide pharmacokinetics. Investigastional New Drugs 1991; 9: 305-11.
35. Kurowski V, Cerny T, Küpfer A, Wagner T. Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 1991; 117 (Suppl 4): 148-53.
36. Hartley JM, Hansen L, Harland SJ et al. Metabolism of ifosfamide during a three-day infusion. Br J Cancer 1994; 69: 931-6.
37. Chang TKH, Waxman DJ. Cyclophosphamide modulates rat hepatic cytochrome p450 2C11 and steroid 5α-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res 1993; 53: 2490-7.
38. Fields K, Elfenbein G, Lazarus H et al. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 1995; 13: 323-32.